DuPont de Nemours, Inc. (NYSE: DD) — A Cleaner Portfolio Priced as a Water Compounder, Still Built Like a Cyclical

Independent equity research note. Report date: 2026-07-10. Fresh initiation (post-Qnity-spin “New DuPont”).

⚡ Claude’s Take

This block is the author’s own independent opinion and general information — not investment advice. The analytical body of this note below carries no buy/sell recommendation and no price target; the single directional view is confined to this box.

Verdict: HOLD — a genuine portfolio upgrade, but priced as a water compounder while it still earns cyclical-materials returns on capital. Constructive on quality, unconstructive on the entry. Fair zone ~$110–135 (≈10.5–12.5x forward EV/EBITDA, ≈15.5–19x forward adjusted EPS ~$7.10). Accumulate on weakness toward ~$105–110; trim into strength above ~$150. Not a short.

The Qnity spin (Nov 1, 2025) and the Aramids sale (closed Apr 1, 2026) did what Ed Breen’s separation playbook was supposed to do: they left behind a cleaner, higher-margin, less-China-exposed DuPont anchored by two genuinely good franchises — Tyvek medical packaging and FilmTec water membranes — inside a ~24% EBITDA-margin business. That is real. What the market is now paying for is a classification: ~12.3x forward EV/EBITDA and ~19x forward adjusted EPS puts “New DuPont” above de-rated diversified chemicals (PPG ~12x/15x) and just under pure-play water (XYL ~14x/21x), i.e., the tape has decided this is a water-and-healthcare compounder. The problem is that the evidence for “compounder” is half-built. Half the company (Diversified Industrials) is a flat-to-shrinking cyclical; water revenue has been dead flat for three years while Chinese entrants commoditize the low end; and the factor model flatly disagrees with the narrative — DuPont loads −0.60 on Growth and +0.94 on Materials, clustering with LIN/PPG/CE/BHP/FCX (chemicals and miners), not with XYL/PNR/ECL. On the returns that actually matter, reported ROIC is ~4.5% (sub-WACC on a goodwill-stuffed balance sheet); the honest cash/tangible ROIC is low-to-mid-teens, decent but not compounder-grade. This is a good business wearing a GAAP mask and a compounder costume.

The framing is quality-at-a-full-price / a post-spin re-rating that has already crested — the stock is ~13% off its February all-time high, momentum has rolled over (rs_peak −12.2, last-quarter return negative), and no insider has bought a single share on the open market even as the company authorizes a $2B buyback. None of that is bearish enough to short a cash-generative, investment-grade name with genuine water/healthcare secular optionality and ~$1.1B of Aramids dry powder — but it is not cheap enough to chase either. Conviction: medium. The single fact that flips me bullish: two-plus consecutive quarters of durable ~6%+ organic growth with margin expansion in Healthcare & Water, which would earn the compounder multiple. The single fact that flips me bearish: a debt-funded, high-multiple healthcare acquisition or a Healthcare & Water growth stall that re-rates the whole thing back toward PPG/PNR ~10x. Tag: “The clean-up is real; the compounder multiple isn’t earned yet.”

📈 Stock Price Action — Five-Year Event Map

Factual price history, not a recommendation. Price moves are FACT; attributed drivers are INTERPRETATION. The AZI price series is back-adjusted for both the Nov-1-2025 Qnity spin distribution and the 2026-06-24 1-for-3 reverse split, so the adjusted path is a single continuous line in today’s per-share terms; unadjusted post-split quotes trade ~$135 (÷3 to compare with pre-split prints).

The arc. Over the trailing 60 months the adjusted-close path ran ~$78.9 (Jul-2021) → trough $53.71 (Sep-26-2022) → all-time high $154.49 (Feb-12-2026) → ~$135 (Jul-10-2026). The stock is ~12.6% off its February high, sits above its 200-day EMA (~$129), and its 52-week adjusted range is ~$85.85 → $154.49. From the Qnity-spin reference point (adjusted ~$100.8 on Oct-31-2025) it is +34%, having peaked at +53% in February before giving roughly a third of the re-rating back.

Cycle narrative. The five-year story is a conglomerate-discount-to-spin-unlock arc. The 2022 trough (#1) was macro/duration-driven and shared with every quality industrial. The Rogers termination (#2) was company-specific and, in hindsight, capital-allocation-positive — DuPont walked from a deal China would not clear (paying a $162.5M reverse-termination fee) and redirected cash to repurchases. The long 2022–24 recovery (#3) was margin normalization after the COVID destocking wave, layered with heavy buybacks. The defining events are #5–#6: the market spent 2025 pre-positioning for the Qnity separation, then paid up hard once “New DuPont” existed as a clean ~24%-EBITDA-margin, water-and-healthcare-weighted business rather than a DowDuPont remnant. The February-to-July give-back (#7) is the re-rating digesting — not a thesis break, but a signal that the “easy” separation money is now in the price.

1. Executive Summary

DuPont de Nemours is, as of this initiation, a fundamentally different company than it was nine months ago. The November 1, 2025 tax-free spin of its Electronics business (Qnity, ticker Q) and the April 1, 2026 close of the Aramids (Kevlar®/Nomex®) sale to the Arclin/TJC platform (~$1.1B net proceeds) completed Ed Breen’s multi-year separation project. What remains — “New DuPont” — is a ~$7.2B-revenue, ~24%-EBITDA-margin specialty-materials company organized into two segments: Healthcare & Water Technologies (FY2025 sales $3,233M, ~30% EBITDA margin — FilmTec reverse-osmosis membranes, Amberlite ion-exchange resins, Tyvek medical packaging, Spectrum/Liveo medical-device and biopharma materials) and Diversified Industrials (FY2025 sales $3,616M, ~22% EBITDA margin — Tyvek house wrap, Styrofoam, Corian, Vespel, Molykote, Betaforce adhesives, Cyrel print plates).

The investment tension is straightforward. The portfolio upgrade is genuine: the RemainCo is higher-margin, less cyclical, and far less China-exposed (~10% of revenue vs. the electronics-heavy pre-spin mix) than the old conglomerate, and it owns two authentically moaty franchises in Tyvek medical and FilmTec water. But the market has re-rated it as a compounder before the compounding has been demonstrated. At ~$135, DuPont trades at ~12.3x forward EV/EBITDA (on guided FY2026 operating EBITDA of ~$1.745B) and ~19x forward adjusted EPS (~$7.10 post-split) — a full multiple that sits above de-rated diversified chemicals and just below pure-play water. Three facts sit uneasily against that multiple: (1) blended organic growth is low-single-digit and bifurcated (a high-single-digit medical grower, a three-years-flat water business, and a shrinking cyclical half); (2) reported return on invested capital is ~4.5% — below cost of capital — because the balance sheet carries $10.7B of merger-created goodwill and intangibles (the honest cash/tangible ROIC is a decent-but-not-exceptional low-to-mid-teens); and (3) the stock’s empirical factor DNA is cyclical materials, not secular compounder (−0.60 Growth loading, +0.94 Materials, clustering with miners and coatings).

Quality-of-earnings discipline is essential here: GAAP consolidated results are polluted by two overlapping discontinued-operations events, so raw quarterly prints are unusable (Q4 2025 shows negative consolidated “revenue”). The cash generation is real (>5x cash-to-GAAP-income); the accrual losses are optical. The balance sheet is a genuine strength (~1.5x net leverage, comfortable coverage). Capital allocation is a study in contrast — competent, value-additive divestiture surgery paired with a poor lifetime acquisition record (overpaying then impairing; the $162.5M Rogers misfire; pro-cyclical buybacks that peaked at $4.4B in 2022 near the highs). Legacy PFAS liability survives the spin but is bounded (~$185M booked reserve, capped by a three-way cost-sharing MOU, and partly indemnified back to Qnity), with a fresh negative in the July 9, 2026 New York Attorney General suit. No insider has bought a share on the open market. The result is a good business, honestly worth owning at the right price, currently trading at a price that already credits an execution story it has only begun to prove.

2. Business Overview

What New DuPont is. Following the Q4 2025 realignment, DuPont reports in two segments (the prior Electronics & Industrial / Water & Protection structure is retired along with the businesses that populated it). (FACT — FY2025 10-K, filed 2026-02-17, Segment note.)

Segment A — Healthcare & Water Technologies (H&WT): FY2025 net sales $3,233M (47% of company), Operating EBITDA $972M → 30.1% margin. Two businesses:

• Healthcare Technologies (~$1,758M, 2024 $1,568M, 2023 $1,459M): sterile medical packaging and protective garments (Tyvek®, Tychem®), plus specialty medical-device components and contract manufacturing built through the $1.75B Spectrum Plastics acquisition (Aug 2023 — structural heart, electrophysiology, surgical robotics, cardiovascular) and Donatelle (Jul 2024), and biopharma silicones (Liveo®). On the Q1 2026 call, management sized total healthcare at ~$2.0B, of which ~$1.2B is Tyvek (about half medical packaging, the rest garments) and the remainder Spectrum/Liveo. (FACT — 10-K; Q1’26 call, 2026-05-05.)
• Water Technologies (~$1,475M, 2024 $1,408M, 2023 $1,460M): a pure-play filtration/separation franchise — FilmTec™ reverse-osmosis and nanofiltration elements, Amberlite™ ion-exchange resins, INGE™ ultrafiltration modules — into industrial wastewater/energy, municipal & desalination, and microelectronics (ion-exchange serving data-center/semiconductor ultrapure water, ~20% of the ion-exchange line). Bolted on the Sinochem (Ningbo) RO Memtech Chinese membrane asset in Oct 2025. (FACT.)

Segment B — Diversified Industrials: FY2025 net sales $3,616M (53%), Operating EBITDA $800M → 22.1% margin. Two businesses:

• Industrial Technologies (~$2,003M): engineered OEM components — Vespel® polyimide parts, Molykote® specialty lubricants, Betaforce™/Betaseal™ structural/EV-battery adhesives (~$300M of EV-directed sales, growing >20%), Cyrel® flexographic print plates — into automotive/EV, aerospace (a current bright spot), printing and packaging. (FACT.)
• Building Technologies (~$1,613M, down from $1,715M in 2023): building-envelope and interiors — Tyvek® house wrap, Styrofoam™ insulation, Corian® solid surface — into non-residential, residential, and repair-and-remodel construction. (FACT.)

How it makes money. DuPont sells branded, specified, application-engineered materials into regulated or mission-critical uses (medical sterility, water purity, building code, aerospace/auto safety). Revenue is overwhelmingly transactional product sales rather than contracted/subscription — deferred revenue is immaterial — but with high designed-in / specified-in stickiness: a Tyvek-validated sterile package or a FilmTec-specced desalination train is not swapped casually. “Recurring” here means repeat consumable/replacement demand, not backlog. (FACT/INTERPRETATION.)

Geography (FY2025): U.S. $3,188M (47%), EMEA $1,468M (21%), Asia Pacific $1,640M (24% — of which China/Hong Kong $708M = ~10%), Canada $227M, Latin America $326M. (FACT.) The post-spin company is ~50% North America and only ~10% China — materially less China-exposed than the pre-spin electronics-heavy mix, which lowers geopolitical/tariff tail risk versus commodity-chemical peers. (INTERPRETATION.)

Other structural facts. ~13,300 go-forward employees (after ~1,700 depart with Aramids). R&D expense $193M = 2.8% of sales — strikingly low for a self-styled “science” company; the R&D-heavy electronics platform left with Qnity. SG&A $1,019M; intangible amortization $291M (acquisition-driven). (FACT.)

Recurring vs. cyclical mix. Roughly half defensive-secular (H&WT: non-discretionary medical and water replacement demand) and half early/mid-cyclical (Diversified Industrials: construction and industrial capex). (INTERPRETATION.)

Verdict. A cleaner, higher-margin, less-China-exposed specialty-materials portfolio than the old conglomerate, anchored by two genuinely differentiated franchises (medical Tyvek, FilmTec water) plus a cyclical industrials tail. It is decidedly better than the flat/no-growth commodity-chemical profile of a Dow — but it is not a pure water/medical compounder: over half of revenue is construction- and industrial-cyclical, and the science-and-R&D intensity that would justify a compounder label left with the electronics spin.

3. Industry Dynamics

DuPont’s industry exposure is a barbell: two structurally attractive, high-barrier oligopolies bolted to two cyclical, competitive, commoditizing-at-the-edges markets.

Water treatment / membranes & resins (~$1.5B). Global water and wastewater treatment is a large (>$300B across equipment/chemicals/services), structurally growing market driven by scarcity, reuse/desalination, ultrapure industrial water (semiconductors, pharma, data-center cooling), and tightening regulation — including U.S. PFAS drinking-water rules with compliance deadlines around 2029, a demand tailwind for treatment media. The membrane-element/resin product niche DuPont occupies is more concentrated than the broad services market. Named competitors: Toray, Nitto Denko/Hydranautics, LG Chem, Veolia/Suez, LANXESS (Lewatit resins), Pentair (X-Flow), Ecolab/Nalco (treatment-chemistry adjacency). This is a structurally attractive, oligopolistic sub-industry — high qualification barriers, replacement-consumable demand — though Chinese entrants (the very reason DuPont bought Sinochem’s RO asset) are pushing commoditization at the low/standard end. Verdict: good industry. (FACT/INTERPRETATION.)

Medical packaging & device components (~$1.76B). Sterile medical packaging is an oligopoly with enormous regulatory switching costs — changing a sterile-barrier material triggers re-validation and re-filing with the FDA/notified bodies. Tyvek is the de-facto standard substrate; adjacent packaging converters (Amcor, Berry Global, Oliver Healthcare Packaging) largely convert Tyvek rather than replace it. The device-components/contract-manufacturing piece (Spectrum/Donatelle) is more fragmented and competitive — Integer, Resonetics, Nordson MEDICAL, Gerresheimer — a lower-moat, capabilities-based business. Verdict: packaging excellent; device CMO decent-but-competitive. (FACT/INTERPRETATION.)

Building / construction materials (~$1.6B). Cyclical, tied to non-residential + residential + repair-and-remodel construction; the business has declined every year 2023→2025 amid rate-driven weakness and channel destocking. Competitors: house wrap vs. Berry (Typar), Kingspan, Owens Corning; insulation vs. Owens Corning, Kingspan, BASF; solid surface (Corian) vs. Wilsonart, Formica, LG Hausys, Caesarstone. Building codes and Tyvek’s brand specification give durability, but this is a structurally mediocre, cyclical, competitive market. Verdict: middling/cyclical. (FACT.)

Industrial engineered components (~$2.0B). A grab-bag of niche, specified OEM products (Vespel polyimide, Molykote lubricants, Betaforce/Betaseal auto adhesives, Cyrel print plates). Each is a high-spec niche with real qualified-in switching costs, but end-demand is auto/aero/industrial-cyclical and some lines (Cyrel flexo plates) face secular pressure from digital printing. Competitors are diffuse: Henkel/H.B. Fuller (adhesives), Klüber/Fuchs (lubricants), MacDermid/Asahi (flexo plates). Verdict: good niches inside a cyclical, fragmented market. (FACT/INTERPRETATION.)

Capital-cycle read (Marathon lens). The water and medical sub-industries have the hallmarks of durable, supply-disciplined oligopolies (high qualification barriers, consumable replacement demand) where returns can persist. The industrial and building sub-industries are classic cyclical markets where capital chases high returns and mean-reverts — and where DuPont’s own results (Building −3%/yr, Diversified EBITDA −4.6%) show it is on the trailing edge of a construction/industrial downcycle. (INTERPRETATION.)

Overall industry verdict. Structurally above-average but not uniformly good — closer to the “quality water-industrial” profile of Xylem/Pentair than to a commodity-chemical Dow, but held back by the cyclical half. Half of DuPont sits in genuinely attractive, regulation-protected oligopolies; half sits in competitive, cyclical markets.

4. Competitive Position

Naming the moat mechanism (Greenwald taxonomy) franchise-by-franchise:

Tyvek® — a genuine moat: intangibles (proprietary process + patents) + switching costs (regulatory qualification) + brand/specification. Tyvek is made by a unique, capital-intensive flash-spinning process DuPont has protected for decades; in medical it is the specified sterile-barrier substrate embedded in customers’ FDA/CE filings — re-validating an alternative is slow and costly. This is textbook demand-side captivity, and it shows up in Healthcare & Water’s ~30% EBITDA margin. The same material dual-uses into house wrap, where the moat is real but weaker (brand + code specification, more substitutable). This is the single best asset in the RemainCo. (INTERPRETATION grounded in FACT — margins, process history.)

FilmTec™ RO/NF membranes + Amberlite™ resins — moat: membrane-chemistry IP + scale/cost + qualification switching costs. DuPont is a top-tier global membrane maker; membranes are performance-qualified into desalination/industrial systems and replaced on a consumable cadence, giving sticky replacement revenue. Pressure-test: Chinese entrants (Vontron, and the Sinochem asset DuPont just bought rather than competed away) are commoditizing standard brackish/seawater elements — so the moat is real at the high-performance/specialty end, eroding at the commodity end. Water’s flat three-year revenue ($1,460M → $1,475M) is consistent with volume growth offset by price/mix pressure. Genuine but partially contested. (INTERPRETATION/FACT.)

Vespel®, Molykote®, Betaforce/Betaseal, Corian®, Cyrel®, Styrofoam™ — moat: brand + qualified-in switching costs, of varying strength. Vespel (polyimide parts qualified into aero/semis/auto) and the auto structural adhesives are genuinely specified-in and sticky; Corian and Styrofoam are strong brands in weaker, more substitutable categories; Cyrel is a decent brand facing digital-print secular pressure. Collectively these support Diversified Industrials’ respectable-but-lower ~22% EBITDA margin. (INTERPRETATION.)

Kevlar®/Nomex® (Aramids) — a real moat, but DIVESTED. Aramids (a near-duopoly with Teijin/Twaron) left the company on April 1, 2026. Do not credit go-forward DuPont with its economics — only a ~$325M retained minority equity interest in the Arclin holdco remains. (FACT.)

The critical skeptical point — moat vs. return on capital. The product-level moats are real (34.5% gross margin, ~26% segment EBITDA margin, pricing that has held volume-led growth in Healthcare). But the moat does not translate into a high enterprise return on capital, because DuPont overpaid for much of the portfolio via M&A. Continuing-ops goodwill is $7.87B and other intangibles $2.86B — together ~50% of total assets — against only ~$1.6B of company operating EBITDA. On a full, goodwill-inclusive invested-capital base (~$16.5B), normalized after-tax operating profit of ~$745M implies a reported ROIC of ~4.5%, below an ~8–9% chemicals WACC — directly analogous to DuPont’s own ag spinoff Corteva (~7% ROIC on DowDuPont goodwill) and to Xylem (~8% post-Evoqua). On a tangible invested-capital base (~$5.8B, stripping the merger-created intangibles current management never paid cash for), cash ROIC is a healthier ~13% and ROTCE ~17%. The truth sits between the two: DuPont earns decent low-to-mid-teens cash returns on the capital it actually deploys, but sub-WACC returns on the acquisition premiums permanently embedded in its book. (FACT/INTERPRETATION.)

Verdict. DuPont owns two-to-three genuinely durable, high-margin franchises (medical Tyvek, FilmTec water, select engineered niches) plus a longer tail of good-brand-but-cyclical products — a narrow-to-moderate, differentiated moat, not a wide one, whose quality is masked at the enterprise-ROIC line by M&A goodwill. “Durable advantage at the product level, unexceptional returns at the enterprise level.”

5. Growth History and Forward Opportunities

Multi-year revenue history (continuing ops, by business, $M): (FACT — 10-K MD&A.)

Volume vs. price. FY2025: local price −1%, currency 0%, volume +3%, portfolio 0% → +2% reported. By segment 2025: H&WT +9% (volume +7, portfolio +1, currency +1, price 0) — a genuinely strong, volume-led, price-neutral result; Diversified Industrials −3% (price −1, volume −1, portfolio −1). Q1 2026 (first fully clean post-spin quarter): total sales $1,681M, +4.3%; H&WT $806M (+5.6%), EBITDA $244M (30.3% margin); Diversified $875M (+3.1%), EBITDA $200M (22.9%). (FACT.)

Quality of growth. The engine is Healthcare Technologies (organic volume + Spectrum/Donatelle M&A). Caution: part of the +7% 2025 volume is restocking after a 2024 healthcare-channel destock — some is cyclical recovery, not pure secular. Water Technologies has been flat for three years — volume growth offset by price/commodity-membrane pressure and Chinese competition. Diversified Industrials has shrunk, dragged by construction. So headline ~2% three-year growth masks a two-speed portfolio: a high-single-digit medical grower, a flat water business, and a declining cyclical half. (INTERPRETATION.)

Forward opportunities (real, but partly cyclically-timed):

• Water: scarcity, reuse/desalination, ultrapure industrial/data-center water, and PFAS-remediation regulation (compliance ~2029) — a durable decade-long backdrop shared with XYL/PNR. Capture depends on defending the high-performance membrane niche against Chinese commoditization (hence the Sinochem buy). (FACT/INTERPRETATION.)
• Healthcare: aging demographics, device complexity (surgical robotics, structural heart), and biologics driving sterile-packaging and precision-component demand — genuinely secular; management sees healthcare landing mid-to-high single digits in 2026. (FACT — Q1’26 call.)
• Industrial/Building: cyclical recovery optionality — Building Technologies is at a multi-year construction trough, so a rate-cut/remodel recovery is leverage, not secular growth. EV battery adhesives (~$300M, growing >20%) are a modest structural theme against soft auto volumes. (FACT/INTERPRETATION.)

Management’s algorithm. New DuPont is framed as a higher-growth, higher-margin multi-industrial targeting mid-single-digit organic growth with 150–200bps of margin expansion over three years (2025 Investor Day), plus bolt-on M&A and a mix-shift from ~50/50 toward 2/3 Healthcare & Water. That is plausible for H&WT but a stretch for the blended company given the cyclical half and flat water line. (INTERPRETATION / OPEN QUESTION.)

Verdict. Medium-quality, two-speed growth. One genuinely attractive secular grower (Healthcare, high-single-digit, volume-led), one structurally-tailwinded-but-flat business fighting commoditization (Water), and a cyclical half that has been a drag but carries recovery optionality. Better than a no-growth commodity chemical; not a clean secular compounder — and a meaningful slice of the 2025 pickup is post-destock restocking, not durable acceleration.

6. Financial Quality

The clean base — and a reconciliation flag. Post-spin continuing operations (excluding both Qnity and Aramids) run FY2025 net sales $6,849M (2024 $6,719M; 2023 $6,614M) and total Operating EBITDA $1,628M (segment $1,772M less Corporate $144M) = 23.8% margin. Management’s FY2026 guidance (raised on the Q1 call) is net sales ~$7,185M, operating EBITDA ~$1,745M (~24.3% margin), adjusted EPS $2.35–2.40 (pre-split). Note that ROIC/aggregator “TTM sales ~$6.1B / EBITDA ~$1.30B” figures do not tie to the filings — they capture messy Qnity-transition and discontinued-ops quarters and should be discarded in favor of the $6.85B/$1.63B trailing base and the $7.19B/$1.745B forward guide. (FACT — 10-K recon; Q1’26 call.)

Margin trajectory — real, but from subtraction. Continuing gross margin rose 32.8% (2023) → 33.0% (2024) → 34.5% (2025) → 35.8% (Q1 2026). This is a genuine mix-driven step-up — but it is the product of removing lower-margin electronics (Qnity) and aramids, leaving a higher-margin residue anchored by the ~30%-EBITDA-margin Healthcare & Water segment. Investors should not extrapolate it as pricing power or scale economics: Healthcare & Water shows classic operating leverage (+15% EBITDA on +8.6% sales), Diversified Industrials shows the opposite (−4.6% EBITDA). Do economics improve with scale? Partially — in one segment, not the other. (FACT/INTERPRETATION.)

Quality of earnings — three layers of noise. GAAP continuing net income was only ~$98M in FY2025 (a distorted 51% effective tax rate on a low pretax base), implying a ~0.7% GAAP ROE that is not representative. Strip: (1) Significant items ($412M in 2025, $380M in 2024, $784M in 2023) — separation/transaction costs, restructuring, litigation/PFAS, intangible charges, largely spin-related and rolling off; (2) acquired-intangible amortization inside the $647M D&A — a large non-cash charge from the 2015–2019 Dow/DuPont reshuffle and Spectrum/Laird deals; (3) discontinued-ops swings — Q4 2025 consolidated GAAP shows negative “revenue” and −$652M operating income purely from Qnity spin accounting. Any analyst using raw consolidated GAAP quarterly prints here will get garbage — this is the confirmed gotcha. (FACT.)

Adjusted earnings power — two definitions, know the difference. Management’s guided FY2026 adjusted EPS of ~$2.35–2.40 pre-split ≈ $7.05–7.20 post the 1-for-3 reverse split excludes intangible amortization and uses the clean post-spin low-interest structure. A stricter definition that expenses acquired-intangible amortization (a real economic cost of the acquired businesses) lands closer to ~$4–5 post-split. The honest read: the “true” P/E on ~$135 is ~19x on management’s definition and closer to ~27–30x if you insist on charging amortization — present both; the answer sits between. Cash generation confirms the GAAP depression is optical: FY2025 continuing operating cash flow was $560M vs. $98M GAAP net income (>5x). (FACT/ASSUMPTION, labeled.)

Free cash flow and capex. FY2025 continuing operating cash flow $560M; capex $333M (~4.9% of sales — light, typical of a specialty portfolio; environmental capex only $7M) → reported FCF ~$227M, artificially depressed by separation cash costs and elevated cash taxes. Normalizing for ~$300–400M of one-time separation costs that abate through 2026 implies normalized FCF power of ~$700–900M → ~4–5% FCF yield on the ~$18.8B market cap — decent, not cheap. (Caution: ROIC reports FY2025 capex as $55M — wrong; use the 10-K’s $333M.) (FACT.)

ROIC vs. WACC — the goodwill-denominator trap. As covered above in Competitive Position: reported ROIC ~4.5% (sub-WACC) on ~$16.5B goodwill-inclusive invested capital; cash/tangible ROIC ~13% and ROTCE ~17% on ~$5.8B tangible capital. Book equity of $14.0B is $38.8B of APIC offset by a −$24.2B accumulated deficit (legacy pushdown and prior impairments); tangible common equity is only ~$3.3B. Present both denominators to the reader; the economically meaningful figure is the cash/tangible return, and it is decent — not compounder-grade. (FACT/INTERPRETATION.)

Balance sheet — a clear strength. Q1 2026: total debt $3,172M, cash $710M → net debt $2,462M ≈ 1.5–1.6x run-rate operating EBITDA; current ratio 2.68x; EBITDA/interest ~9.7x. In November 2025 DuPont repaid $1,850M of maturing notes at par using Qnity separation proceeds (total debt fell from $8.9B in Q3 to $3.2B in Q4 as Qnity took ~$4B on separation). Pension/OPEB net liability is immaterial ($414M; most legacy pension left in 2019). ~$1.1B of Aramids cash landed in Q2 2026. (FACT.)

Verdict. New DuPont is a decent, cash-generative specialty business — not a high-return compounder, and not a value-destroyer either. The quality is concentrated in the Healthcare & Water leg (~30% margins, mid-teens EBITDA growth, genuine operating leverage); Diversified Industrials is a flat, cyclical drag. Earnings quality is low on a GAAP basis but high on a cash basis — provided the reader does the discontinued-ops and goodwill adjustments. “Good business, only partly proven at scale, wearing a GAAP mask.”

7. Capital Allocation

Use of proceeds — the strategic reshaping. DuPont’s capital story since 2021 is serial portfolio surgery: shed commodity/cyclical and electronics; concentrate on higher-multiple Healthcare/Water plus differentiated industrials.

• Qnity Electronics spin (Nov 1, 2025): tax-free distribution, one Qnity share per two DD shares. Qnity took ~$4B of debt on separation; DuPont used separation cash to retire $1.85B of notes — a deleveraging spin, well-executed.
• Aramids divestiture (~$1.8B gross / ~$1.1B net, closed Apr 1, 2026): exits Nomex/Kevlar. But note the $768M goodwill impairment taken on Aramids before sale — DuPont sold at a loss to carrying value, a tacit admission the asset was over-marked. A mark against prior deployment even as the exit is sensible. (FACT.)

M&A history — discipline is mixed. (FACT.)

• Spectrum Plastics (Aug 2023, ~$1,781M cash): medical device components → on-thesis, full multiple, but in the good segment.
• Donatelle (Jul 2024): medical bolt-on.
• Laird Performance Materials (2021, ~$2.3B): EMI shielding — migrated into Electronics/Qnity, now spun off.
• Rogers Corp (2021 agreement, ~$5.2B): terminated Nov 2022 after failing to clear China SAMR; DuPont paid a $162.5M reverse-termination fee and lost ~18 months.

Read. Management is a competent portfolio surgeon on divestitures, a mediocre acquirer — it overpaid for assets it later impaired (Aramids/Laird lineage), and mis-underwrote a major acquisition’s regulatory path (Rogers). The bolt-on medical strategy (Spectrum/Donatelle) is the most defensible thread. The repeated impairments and the −$24.2B accumulated deficit are the fingerprint of years of buying high and writing down — the Marathon capital-cycle warning sign — even though management is now, correctly, on the right side of the cycle (divesting cyclical, keeping defensive-growth). (INTERPRETATION.)

Dividends. Post-Qnity the Board reset the quarterly dividend from $0.41 to $0.20/sh ($0.60 post the 1-for-3 split; ~$2.40/yr, ~$334M) — a ~1.75% yield at ~$137, ~48% of normalized FCF, moderate and covered. (FACT.)

Buybacks — real, large, and pro-cyclical. DuPont is an aggressive serial repurchaser: $4.375B (2022), $2.0B (2023), $0.5B (2024), $0.5B ASR (2025), $275M ASR (2026), under a $2B authorization approved in Q4 2025. The pattern is the wrong one: peak spend ($4.4B) came in 2022 near a cyclical/valuation high; the pace collapsed to $0.5B in 2024–25 when the stock was arguably cheaper and cash was tied up in the spin. Buy-high, slow-when-cheap — a classic capital-allocation flag. The 1-for-3 reverse split (June 2026) is purely cosmetic — it raised the optical price from ~$45 to ~$137 to look “normal” post-spin; it creates zero value. (FACT/INTERPRETATION.)

Incentive alignment (2026 proxy). STI metrics: Adjusted EPS 50%, Organic Revenue 20%, Adjusted Operating EBITDA 15%, Adjusted FCF 15%. LTI (60% PSU / 40% RSU): Adjusted ROIC + Adjusted Net Income + Relative TSR vs. S&P 500. This is a reasonably well-constructed scorecard — management is explicitly paid on capital efficiency (ROIC) and on beating the index, better than pure EPS-growth plans. Soft spots: (a) all profit metrics are adjusted, so the same significant-items add-backs that flatter the narrative also flatter the bonus; (b) shifting Adjusted ROIC to three discrete one-year targets (from a cumulative three-year hurdle) weakens multi-year accountability through the transition. (FACT/INTERPRETATION.)

Verdict. Mixed-to-adequate. The strategic reshaping is intelligent and is being executed with balance-sheet discipline (deleveraging spin, ~1.5x net leverage, comfortable coverage), and incentives are decently aligned. But the lifetime record is scarred by overpaying-then-impairing, the $162.5M Rogers misfire, and pro-cyclical buybacks. Cautiously positive on go-forward intent; skeptical on the track record. Shareholders should not mistake competent divestiture surgery for a durable record of value-additive deployment — and the ~$1.1B Aramids cash plus $2B buyback is a genuine fork: accretive redeployment vs. an over-priced deal or top-of-market repurchase.

8. Changes and Headwinds — Last Two Years

Portfolio transformation (the dominant story).

• Qnity (Electronics) spin completed Nov 1, 2025 — the defining event; converted a DowDuPont remnant into a focused water/healthcare/industrials RemainCo. (FACT.)
• Aramids sale to Arclin — Kevlar/Nomex; announced Aug-2025, closed Apr 1, 2026 (~$1.1B net; ~$325M retained equity). (FACT.)
• Segment restructure to two segments (Healthcare & Water + Diversified Industrials), ~50/50 today with a stated goal of 2/3 Healthcare & Water. (FACT.)
• Decision to keep Water in the RemainCo — the original 2024 plan contemplated spinning both Electronics and Water; management reversed and retained Water, a material strategy change that put the crown jewel inside DD. (FACT — 2025 8-Ks.)
• Donatelle acquisition (Jul-2024) — medical bolt-on. (FACT.)

Leadership. Ed Breen → Lori Koch — Koch (former CFO) became CEO in mid-2024 with Breen as executive chair; Antonella Franzen is CFO. Breen has been the architect of the serial-separation strategy (Dow/DuPont/Corteva → Qnity); the “value-through-separation” playbook is now institutionalized. (FACT.)

Capital allocation / balance sheet. $2B buyback ($500M + $275M ASRs executed/announced); net leverage ~1.5x; Aramids proceeds add firepower. (FACT.)

Macro / cyclical headwinds. 2022–23 destocking (now lapped); China/semis softness and tariff overhang (less acute post-spin at ~10% China); FX translation; a construction downcycle weighing on Building Technologies; a Middle East logistics disruption that cost water ~$10M in Q1 2026 (mitigated via rerouting), against ~$90M of incremental input costs management expects to fully offset with price/surcharges. (FACT — Q1’26 call.)

PFAS / environmental litigation (live and negative). DuPont, Chemours and Corteva carry legacy PFAS (“forever chemicals”) liability from the 2021 separation cost-sharing MOU. The 2023 public-water-systems MDL settlement (~$1.185B combined across the three) resolved one tranche; DuPont’s $400M contribution was funded (final April 2024). Exposure persists — and on July 9, 2026 the New York Attorney General sued 3M, Chemours, Corteva and DuPont over alleged pollution from consumer products. This is the freshest headline risk and a genuinely open-ended tail. (FACT — ag.ny.gov, 2026-07-09; 10-K Note 16.)

Recent-news skew. The AZI feed is thin (five, largely unscored, articles): a routine earnings-calendar mention; Qnity’s CEO on CNBC (positive but for the spun entity); a Morgan Stanley Equal-Weight with a PT mechanically raised to $156 (reverse-split adjustment plus a modest raise); a “spin-offs unlock value” thought piece featuring DD favorably; and the negative NY AG suit. Net skew: broadly neutral, one clear negative (PFAS), one mild positive (spin-value narrative). A quiet tape — no thesis-changing catalyst. (FACT feed / INTERPRETATION skew.)

Verdict. The changes strengthen the business (cleaner, higher-margin, less cyclical, better balance sheet) but do not de-risk the thesis on valuation — the market has already paid for the improvement, and the one open-ended liability (PFAS) is currently generating negative, not settling, headlines.

9. Risk Analysis

Catastrophic-loss risk. Low at the equity level (investment-grade balance sheet, ~1.5x leverage, diversified cash-generative franchises). The one genuinely open-ended tail is PFAS — a mass-tort liability difficult to bound, where the current headline flow (NY AG) is negative and where DuPont retains counterparty/indemnity backstop exposure if Chemours (the weakest balance sheet of the three) or Qnity cannot fund its share. Chance of a total loss of capital: remote. (INTERPRETATION.)

10. Valuation

Where New DuPont trades. Price ~$135, ~137M shares → market cap ~$18.8B; net debt ~$2.46B + minority → EV ~$21.4B. On guided FY2026 operating EBITDA of ~$1.745B, that is ~12.3x forward EV/EBITDA; on post-split adjusted EPS ~$7.10 (management’s definition), ~19x forward P/E. The TTM optics — 16.5x EV/EBITDA on depressed $1.30B TTM EBITDA, 32.7x EV/EBIT, ~31x GAAP P/E — overstate richness because they capture Qnity-transition quarters; they should not anchor the analysis. (FACT/reconciled.)

Gotcha — flag explicitly. The AZI own-history valuation percentiles (P/B and P/S at the 99.5th, “richest ever”) are contaminated by the pre-spin DowDuPont conglomerate. New DuPont is a smaller, higher-margin, water/healthcare-levered entity with a different multiple entitlement than the ~$20B-revenue chemicals sprawl. Value DD against peers, not its own history — the “richest ever” reading is an artifact and should be discarded. (FACT/INTERPRETATION.)

Peer comp set (forward peer multiples, mid-2026):

Where ~12.3x sits. New DuPont’s forward EV/EBITDA is below premium water/hygiene (ECL ~21x, XYL ~14x), below APD (~16.5x), and roughly in line with de-rated diversified industrials (PPG ~12x, PNR ~12x) — while carrying a ~24% EBITDA margin materially higher than PPG/PNR and closer to the premium cohort. On ~19x forward P/E it is mid-pack (cheaper than XYL/APD, richer than PPG/PNR). On peer-relative terms, DuPont is not richly valued — it is fair, arguably fair-to-slightly-attractive. The stock screens “richest ever” only against a contaminated own-history denominator. (INTERPRETATION.)

Embedded expectations. ~12.3x forward EV/EBITDA and ~19x adjusted P/E underwrite mid-single-digit organic growth (~4–6%) with continued margin expansion toward and beyond the ~24–25% level and a mix-shift toward the higher-margin Healthcare & Water segment (goal: 2/3 of the company). Reverse-engineered against a high-single/low-double-digit adjusted-EPS growth path, that is a ~1.4–1.6x PEG — reasonable if the growth is durable, expensive if DuPont is the −0.60-Growth-loading cyclical the factor model describes. The multiple is not pricing a Dow-style commodity trough, nor an Ecolab-style secular compounder; it prices a credible-but-unproven “focused higher-margin re-rating.” (INTERPRETATION.)

Sum-of-the-parts (warranted, given two clean segments):

• Healthcare & Water Technologies (~30% EBITDA margin — FilmTec, Amberlite, Tyvek medical, Spectrum/Liveo): recurring, regulated, sticky, water-secular. Deserves a premium ~14–16x EV/EBITDA (XYL-to-ECL band).
• Diversified Industrials (~22% margin — building, aerospace, EV adhesives, printing): cyclical, commodity-adjacent. ~8–10x.
• Blended SOTP on ~50/50 EBITDA lands around ~11.5–13x — right where the stock trades. The SOTP supports the current multiple rather than screaming mispricing in either direction; the re-rating catalyst is the mix-shift to 2/3 Healthcare & Water, which would pull the blended fair multiple toward ~13–14x over time. (INTERPRETATION.)

Scenarios (illustrative EV/EBITDA on ~$1.745B FY26 EBITDA; no price target):

• Bear: organic growth stalls to ~0–2% (the cyclical proves out), margins plateau, PFAS escalates; multiple de-rates to the PPG/PNR ~10x band → EV compresses ~20%. Quality was overpaid for at a crested re-rating.
• Base: ~4–5% organic, margins drift to ~25%, mix-shift proceeds, multiple holds ~12–13x → EV roughly flat-to-modestly-higher; total return ≈ EBITDA/EPS growth + ~1.75% dividend.
• Bull: ~6–8% organic (water + healthcare/CDMO), margins toward ~26%, Aramids proceeds redeployed accretively, multiple re-rates toward ~14–15x (XYL band) → meaningful upside from numerator and denominator.

Valuation verdict. Peer-relative fair, not extreme. The entire debate is which multiple entitlement DuPont deserves — a growth-durability question, not a price question. No price target; no recommendation (see Claude’s Take for the single subjective view).

11. Variant Perception

Consensus. The Street likes the story — a focused, higher-margin RemainCo, water/healthcare “crown jewel” mix, clean ~1.5x balance sheet, active buyback, and a proven separation architect delivering the next unlock. The +34% post-spin move and Morgan Stanley’s raised PT reflect a market that has broadly bought the re-rating — but note MS rates it Equal-Weight: consensus is constructive, not euphoric; the easy money is priced. (FACT/INTERPRETATION.)

Strongest bull case. New DuPont is an under-appreciated water/healthcare compounder trading at a diversified-industrial multiple. At ~12.3x forward EV/EBITDA it sits ~2 turns below XYL and ~9 below ECL despite a higher EBITDA margin than either, with a Healthcare & Water segment (FilmTec, Tyvek, Spectrum/Liveo) of genuine moat characteristics — recurring, regulated, sticky, secular. As the mix shifts to 2/3 Healthcare & Water and Aramids proceeds redeploy accretively, the blended fair multiple drifts toward the XYL/ECL band, driving both EPS growth and a re-rate. The SOTP already supports today’s price; the mix-shift is free optionality.

Strongest bear case. The factor model tells the truth the narrative hides — DD is a −0.60-Growth-loading, +0.94-Materials-beta cyclical, clustered with LIN/PPG/CE/BHP/FCX, not with XYL/PNR/ECL. The “premium water compounder” framing is a re-rating imposed on a business whose statistical DNA is cyclical materials and whose reported ROIC is sub-WACC. The +53% spin pop has already crested; organic growth is more likely mid-single-digit-cyclical than secular; PFAS is open-ended and escalating (NY AG 7/9/26); and stranded-cost elimination is unproven. At ~19x P/E the market is paying a compounder multiple for a business that may re-rate down toward PPG/PNR ~10–12x on the first growth stumble — with no insider willing to buy a share at these levels.

The assumptions that matter most. (1) Is the growth real and secular, or cyclical? — the whole multiple hangs here. (2) Does the Healthcare & Water ~30% margin hold and expand as it becomes 2/3 of the company? (3) Can stranded post-spin costs be fully eliminated to hit ~24.3%? (4) How bounded is PFAS after the NY AG action and given co-obligor counterparty risk? (5) Is the Aramids cash / buyback deployed accretively?

Falsification. Bull falsified by: two consecutive quarters of flat/negative Healthcare & Water organic growth; a margin plateau below ~24%; a debt-funded high-multiple deal; a large adverse PFAS judgment. Bear falsified by: sustained ~6%+ Healthcare & Water organic growth with margin expansion toward ~26%; the Growth/Momentum factor loadings flipping positive as the market re-classifies DD from “materials cyclical” to “water compounder”; a PFAS global settlement that caps the liability.

Factor-positioning synthesis. The most actionable variant insight is the tension between the fundamental “premium water” narrative and the statistical “cyclical materials” identity (−0.60 Growth, +0.94 Materials, clustered with miners/coatings, momentum crested). Consensus may be offsides in classifying DD as a compounder — if it is really a cyclical, the ~12.3x/~19x multiple is full and the crested momentum is an early warning. Conversely, if management executes the mix-shift, the factor model is looking backward at a company that no longer exists post-Qnity, and the value lives in the re-classification. Either way, the peer-relative valuation is fair, not extreme. (INTERPRETATION.)

12. Fact vs. Interpretation Table

13. Open Questions

1. Stranded-cost quantum and timeline. Management cites ~$30M of stranded costs to remove over two years (~$10M in FY26). Full elimination is baked into the ~24.3% guided margin — unproven; confirm the run-rate exit.
2. PFAS residual net exposure. The exact “Applicable Percentage” of Legacy Liabilities shifted to Qnity via indemnity, and DuPont’s backstop exposure if Chemours (weakest balance sheet) or Qnity defaults, are not fully quantified in the filings — and personal-injury/MDL claims could exceed the MOU’s “qualified spend” definition.
3. Aramids-proceeds redeployment. ~$1.1B net cash plus a $2B buyback authorization — debt paydown vs. repurchase vs. M&A is a live capital-allocation fork; the mix will shape both leverage and per-share economics.
4. Reconciling the go-forward EBITDA base. Filing-based FY2025 continuing EBITDA (~$1.63B) vs. the FY26 guide ($1.745B) vs. lower aggregator “TTM” figures — the clean run-rate should be documented before any tighter valuation is struck.
5. Water re-acceleration. Water revenue has been flat three years; whether the secular tailwinds (desalination, PFAS treatment, data-center water) actually re-accelerate the line — or Chinese commoditization continues to offset volume — is the swing factor for the “compounder” thesis.

14. What Must Be True

Bull case — what must be true, and its falsification test. DuPont must prove it is a water/healthcare compounder, not a cyclical: Healthcare & Water sustains ~6%+ organic growth with ~30%+ and rising EBITDA margins as it grows to 2/3 of the company; water revenue re-accelerates off its three-year plateau; and stranded costs are eliminated to lift blended margin toward ~26%. If so, the ~19x/~12.3x multiple is not just justified but low relative to the XYL/ECL cohort the business would then resemble. Falsification test: two consecutive quarters of flat-or-negative Healthcare & Water organic growth, or a blended EBITDA margin that plateaus below ~24%, breaks the compounder thesis and re-rates the stock toward diversified-industrial multiples.

Bear case — what must be true, and its falsification test. DuPont must be revealed as a cyclical materials business wearing a compounder costume: blended organic growth reverts to ~0–2% as the construction/industrial downcycle bites and water stays flat; reported sub-WACC returns on capital reassert themselves as separation tailwinds fade; PFAS liability escalates beyond the booked reserve; and management deploys the Aramids cash into an over-priced deal or top-of-market buyback. If so, ~19x P/E is a full price for ~4% growth and mid-single-digit ROIC, and the crested momentum resolves lower. Falsification test: sustained ~6%+ Healthcare & Water organic growth with margin expansion, plus the Growth/Momentum factor loadings turning positive as the market re-classifies the name — evidence the post-Qnity company genuinely broke from its cyclical DNA.

15. Source Appendix

See the separate Source Appendix (Appendix B in the combined report) for the full citation list. Primary sources relied upon:

• DuPont FY2025 Form 10-K (filed 2026-02-17) — segment structure, MD&A, cash flow, balance sheet, PFAS/contingencies (Note 16), significant-items reconciliation.
• DuPont Q1 2026 Form 10-Q (filed 2026-05-05) — first clean post-spin quarter, Aramids discontinued-ops (Note 3), goodwill impairment.
• DuPont Q1 2026 earnings call transcript (2026-05-05) — FY26 guidance, segment detail, capital allocation, PFAS update.
• DuPont 2026 DEF 14A (filed 2026-04-10) — incentive metrics.
• EDGAR Form 4 corpus (May–June 2026) — insider transactions.
• ROIC.ai — enterprise value, statements, ratios (reconciled to filings; pre-spin figures discarded where Qnity-contaminated).
• AZI — price CSV (5-year event map), news feed, valuation percentiles (flagged as own-history-contaminated).
• FactorsToday — factor loadings, leaderboard, related-stocks (factor positioning).
• Public peer data — PPG, APD, DOW, LYB, ALB, CTVA, XYL, PNR, ECL (public filings and market data for peer valuation multiples and industry framing).
• New York Attorney General press release (ag.ny.gov, 2026-07-09) — PFAS suit.

The analytical body of this note carries no buy/sell recommendation and no price target; the single directional view is confined to the opening opinion block.

APPENDIX A — Standard Diligence Questionnaire

DuPont de Nemours, Inc. (NYSE: DD) — as of 2026-07-10

Supplemental to the note. Fact / Interpretation / Assumption labels where material.

General

What thoughtful questions have other investors asked about this company? The dominant investor questions post-spin are: (1) Is “New DuPont” a water/healthcare compounder or a cyclical materials company in disguise? — the entire multiple debate; (2) Will management redeploy the ~$1.1B Aramids proceeds and $2B buyback accretively, or repeat the overpay-then-impair pattern?; (3) How bounded is the residual PFAS liability after the Qnity indemnity and the NY AG suit?; (4) Can the ~30% Healthcare & Water margin hold and expand as it becomes 2/3 of the company?; and (5) Is the 2025 growth pickup durable or post-destock restocking? (Interpretation, from the Q1’26 call Q&A and factor read.)

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Mixed. Healthcare & Water is near a normalized-to-slightly-recovering level (medical restocking after a 2024 destock); Diversified Industrials (Building especially) is at a multi-year construction/industrial trough — so the blended company is neither at a clean high nor low, with cyclical upside optionality in the industrial half. (Interpretation.)

Driven by the external environment or internal actions? Both — but the recent margin/EPS step-up is primarily internal (portfolio subtraction: spinning low-margin electronics, selling aramids), not external demand. Organic volume (+3% FY25) is external. (Interpretation.)

How stable are revenues? Moderately. ~50% (Healthcare & Water) is defensive/replacement-driven and stable; ~50% (Diversified Industrials) is cyclical and has been declining. Blended three-year revenue CAGR is a modest +1.8%. (Fact.)

Outlook for products/services? Secular tailwinds in water (scarcity, desalination, PFAS treatment, data-center water) and healthcare (aging demographics, device complexity, biologics); cyclical recovery optionality in building/industrial. (Fact/Interpretation.)

How big will this market be — growing, shrinking, domestic or international? Water treatment (>$300B, growing) and medical packaging/devices (growing, regulated) are large secular markets; building products and general industrial are mature/cyclical. Revenue is ~47% U.S., ~24% Asia (only ~10% China), ~21% EMEA — genuinely international but North-America-anchored. (Fact.)

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Barbell: water membranes face rising Chinese low-end competition (commoditization); medical packaging remains a stable, high-barrier oligopoly; building/industrial are competitive and fragmented. (Interpretation.)

How profitable is the business (ROIC, ROE)? Reported ROIC ~4.5% (sub-WACC), GAAP ROE ~0.7% (distorted) — both dragged by ~$10.7B merger goodwill/intangibles and discontinued-ops noise. Cash/tangible ROIC ~13%, ROTCE ~17% on the capital management actually deploys. The honest answer: decent cash returns above cost of capital, unexceptional returns on the full goodwill-laden base. (Fact/Interpretation.)

How profitable is the industry — competitors, barriers to entry? Water/medical sub-industries: high barriers (qualification, IP, regulation), attractive economics. Building/industrial: lower barriers, cyclical, thinner. (Interpretation.)

Can the business be easily understood? Reasonably, at the product level — but the financials are hard to read through the Qnity/Aramids discontinued-ops accounting; raw GAAP prints are misleading. (Interpretation.)

Can it be undermined by foreign low-cost labor? Partly — Chinese membrane manufacturers are commoditizing the low end of water (the reason DuPont bought Sinochem’s RO asset). Medical packaging and specified engineered niches are better insulated. (Fact/Interpretation.)

Do brands matter? Yes — Tyvek, Kevlar (divested), FilmTec, Corian, Vespel are genuine specified/brand assets; specification into regulated filings (medical) or codes (building) is the moat mechanism. (Interpretation.)

What is the nature of competition? Performance qualification, regulatory specification, IP/process, and (at the commodity edge) price. (Interpretation.)

Customers’ switching costs? High in medical packaging (FDA/CE re-validation) and qualified engineered components; moderate in water (system qualification); low at commoditized membrane/print-plate edges. (Interpretation.)

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The Tyvek/FilmTec brand and process IP are internally-generated and under-carried; conversely, ~$10.7B of acquired goodwill/intangibles is arguably over-carried (evidenced by the $768M Aramids impairment before sale). (Interpretation.)

Off-balance-sheet liabilities? PFAS cost-sharing exposure beyond the booked $185M indemnification reserve — capped by the 3-way MOU ($4B/2040) but with counterparty/indemnity tail risk and litigation (NY AG) potentially exceeding “qualified spend.” (Fact/Open Question.)

How conservative is the accounting? Management reports heavily on adjusted figures (excluding significant items and intangible amortization), and grades incentives on them — a flag. But cash generation exceeds GAAP income >5x, so the direction of adjustment is defensible (non-cash charges). Overall: adjusted-metric-reliant, not aggressive on cash. (Interpretation.)

How CapEx-hungry? Light — capex ~$333M = ~4.9% of sales; specialty, not heavy-chemical intensity. (Fact.)

Capital Allocation & Management

How much FCF, and how is it used? Reported FY25 continuing FCF ~$227M (separation-cost-depressed); normalized ~$700–900M. Used for dividends (~$334M/yr post-reset), large buybacks ($2B authorization; $500M + $275M ASRs), bolt-on M&A, and debt paydown. (Fact/Assumption.)

Philosophy? Serial portfolio surgery (divest cyclical/electronics, concentrate on Healthcare & Water) + aggressive buybacks + moderate dividend + bolt-on medical M&A. (Interpretation.)

Significant acquisitions recently? Spectrum Plastics ($1.78B, 2023, medical), Donatelle (2024), Sinochem RO (2025). Rogers ($5.2B) terminated 2022 ($162.5M fee). (Fact.)

Buying back shares? Yes, aggressively — but pro-cyclically (peak $4.4B in 2022 near highs). (Fact/Interpretation.)

Issuing large amounts of stock to insiders? No unusual issuance; SBC is routine; recent Form 4s are grants (code A) and tax-withholding (code F), no open-market buys. (Fact.)

Compensation policy? STI: adj EPS 50% / organic revenue 20% / adj EBITDA 15% / adj FCF 15%. LTI (60% PSU/40% RSU): adjusted ROIC + adjusted net income + relative TSR. Above-average alignment (pays on ROIC and relative TSR), but all-adjusted metrics. (Fact.)

Motivations of management? Deliver the separation-value-creation playbook (Breen legacy) and re-rate the RemainCo; incentives point at ROIC/relative-TSR, which is constructive. (Interpretation.)

Valuation & Market Data

ADR, MLP, or K-1? No — U.S. C-corp common stock (NYSE: DD), standard 1099. (Fact.)

Dividend policy? Reset post-spin to $0.20/qtr ($0.60 post-split; ~$2.40/yr, ~1.75% yield, ~48% payout). (Fact.)

How profitable? ~24% EBITDA margins; decent cash ROIC; sub-WACC reported ROIC (goodwill). (Fact/Interpretation.)

Is net income diverging from cash from operations? Yes, sharply — FY25 GAAP net income ~$98M vs. operating cash flow $560M (>5x), driven by non-cash amortization, impairments, and separation charges. The divergence is quality-positive here (cash exceeds accrual income). (Fact.)

Risks & Downside

What factors would cause the stock to decline? A growth stall in Healthcare & Water (re-rate toward PPG/PNR ~10x); PFAS escalation; an over-priced acquisition; a deeper construction/industrial downcycle; broad multiple compression in materials; the crested momentum resolving lower. (Interpretation.)

Risk of a catastrophic loss? Low at the equity level — investment-grade, ~1.5x leverage, diversified cash-generative franchises. The one open-ended tail is PFAS. (Interpretation.)

Chance of a total loss? Remote. (Interpretation.)

Recent News & Events

Has the business environment changed recently? Yes, structurally — Qnity spin (Nov 2025) and Aramids sale (Apr 2026) redefined the company; a 1-for-3 reverse split (Jun 2026) reset the optical price. Operating environment: Middle East logistics disruption (managed), ~$90M input-cost inflation (offset by price/surcharges), construction weakness, healthcare recovery. (Fact.)

Significant acquisitions? Sinochem RO (2025), Donatelle (2024), Spectrum (2023). (Fact.)

Change in accounting policies? Segment realignment to two segments (Q4 2025); Aramids reclassified to discontinued ops (Q1 2026). (Fact.)

Recent changes — markets, facilities, management? CEO transition Breen→Koch (2024); new 2035 sustainability goals; AI/digital-lab collaborations; FilmTec nanofiltration launches; $2B buyback + dividend reset. (Fact.)

APPENDIX B — Source Appendix

DuPont de Nemours, Inc. (NYSE: DD) — Research as of 2026-07-10

Primary sources first. All sources below are public.

1. SEC filings (primary — US filer, CIK 0001666700; mirrored locally in output/DD/sources/)

2. Company communications (primary)

• DuPont Q1 2026 earnings call transcript (2026-05-05) — FY2026 guidance (sales ~$7.185B, operating EBITDA ~$1.745B, adjusted EPS $2.35–2.40 pre-split), segment detail, capital allocation, PFAS update, Middle East exposure. (Via ROIC.ai transcript tool; reconciled to press release.)
• DuPont Investor Relations (dupont.com/investors) — Investor Day margin/mix targets (150–200bps expansion; 2/3 Healthcare & Water goal), earnings slides, sustainability report.

3. Quantitative data sources (third-party; reconciled to filings)

• ROIC.ai — enterprise value ($21.4B), income statement, balance sheet, profitability/credit ratios, per-share data, valuation multiples. Caveat: pre-spin periods contaminated by Qnity; ROIC mis-states FY2025 capex as $55M (10-K: $333M) — filing figures used.
• Market price & news data — 5-year adjusted/unadjusted daily price history (five-year event map) and recent news flow; own-history valuation percentiles were flagged as pre-spin-conglomerate-contaminated and discarded for cross-sectional valuation.
• FactorsToday — factor loadings (Momentum −0.02, Value, Quality, Growth −0.60, Materials +0.94), leaderboard (y1 +45.9%/Sharpe 1.42; m3 negative), stock-info (beta ~1.15, alpha −0.019, rs_peak −12.2), related-stocks (LIN/PPG/OLN/CE/BHP/FCX).

4. Peer / industry cross-reference (public data)

• PPG (2026-06-28), APD (2026-06-20), DOW (2026-06-14), LYB (2026-06-09), ALB (2026-06-06), CTVA (2026-06-26), XYL (2026-06-27), PNR (2026-07-10), ECL (2026-06-19) — peer valuation multiples, water-industry framing, DowDuPont-breakup-goodwill pattern (CTVA), commodity-chemical contrast (DOW).

6. Regulatory / litigation

• New York Attorney General press release (ag.ny.gov, 2026-07-09) — suit against 3M, Chemours, Corteva, DuPont over alleged PFAS pollution from consumer products.
• 2023 PFAS public-water-systems MDL settlement (~$1.185B combined across DuPont/Chemours/Corteva; DuPont $400M contribution, final April 2024).
• Jan 22, 2021 DuPont/Chemours/Corteva PFAS cost-sharing Memorandum of Understanding (50% Chemours / 50% DuPont+Corteva; capped at $4B qualified spend or 2040).

All primary filings are available on SEC EDGAR (CIK 0001666700) and the company IR site.